2-((TERT-BUTOXYCARBONYL)(METHYL)AMINO)-2-(4-METHOXYPHENYL)ACETIC ACID, 95.0%, 5g

3-(3-Aminopropyl)-1-methyl-1H-imidazol-3-ium chloride, 98%, 25g

(S)-2-(((Benzyloxy)carbonyl)amino)-3-(p-tolyl)propanoic acid, 98%, 1g

2-(4-Oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid, 98.0%, 10mg

methyl 2-hydroxy-4-(2-methoxyphenyl)-4-oxobut-2-enoate, 97%, 1g

(R)-(-)-a-Methoxy-a-trifluoromethylphenylacetyl chloride, 98.0%, 100mg

2-(Methylsulfonyl)nicotinonitrile, 98%, 5g

Propan-2-one O-benzoyl oxime, 97%, 25g

Plan PLPHi S100x/1.25 phase contrast IOS infinity corrected lens

2-(2-Bromo-4-(tert-butyl)phenoxy)acetic acid, 98%, 250mg

(5-Fluoro-2-isopropoxypyridin-4-yl)boronic acid, 95.0%, 100mg

1-Chloronaphtho[2,3-b]benzofuran, 98%, 250mg

4-(hydroxyimino)-1,2,3,4-tetrahydropyrimidin-2-one, 95+%, 250mg